Amoxycillin Sodium

證據等級: L5

預測適應症: 0 個

Amoxycillin Sodium: Regulatory Status Review — No Repurposing Predictions Available

One-Sentence Summary

Amoxycillin Sodium is a broad-spectrum penicillin-class antibiotic widely used for bacterial infections including respiratory tract, urinary tract, and skin infections. The TxGNN model did not generate any repurposing predictions for this drug in the current run — this report documents its Malaysia regulatory status and outlines the data gaps that must be resolved before a repurposing analysis can be completed. No clinical trial or literature evidence for a new indication is available at this time.

Quick Overview

Item	Content
Original Indication	Bacterial infections (broad-spectrum antibiotic; package insert details not yet retrieved)
Predicted New Indication	None — no TxGNN prediction generated
TxGNN Prediction Score	N/A
Evidence Level	N/A (no prediction available)
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing prediction was generated by TxGNN for Amoxycillin Sodium in this run. Therefore, a mechanistic link between a new indication and the drug’s original use cannot be established at this stage.

Currently, detailed mechanism of action data is not available in the system. Based on general pharmacological knowledge, Amoxycillin Sodium is a broad-spectrum beta-lactam antibiotic belonging to the penicillin class. It exerts its antibacterial effect by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), ultimately leading to cell lysis. Its established indications include infections of the respiratory tract, urinary tract, skin, and soft tissues, among others.

Before a repurposing analysis can proceed, the DrugBank record must be linked (DrugBank ID is currently missing), the MOA must be formally captured in the system, and the TxGNN pipeline must be re-run with correct drug entity mappings to generate candidate indications.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	—

Note: Although 1 active registration is recorded in the system, all product-level details (authorisation number, product name, dosage form, approved indication) were not retrieved in the current data pull. Please query the NPRA product search portal directly (https://www.npra.gov.my/) to obtain the full licence record.

Safety Considerations

Please refer to the package insert for full safety information. No DDI data, key warnings, or contraindications were available in the current evidence pack.

As a general note, Amoxycillin is contraindicated in patients with a known hypersensitivity to beta-lactam antibiotics (penicillins, cephalosporins). Clinically relevant interactions include reduced efficacy of oral contraceptives and increased risk of bleeding with anticoagulants — these should be confirmed against the official Malaysia-registered package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline did not produce any repurposing candidates for Amoxycillin Sodium, and critical data inputs (DrugBank ID linkage, MOA, package insert details, licence record) are missing. The report cannot proceed to an evidence synthesis stage without these foundations.

To proceed, the following is needed:

[Blocking] Retrieve the NPRA full licence record — download the product’s package insert PDF to extract approved indications, warnings, and contraindications
[Blocking] Resolve DrugBank ID mapping — Amoxycillin Sodium should map to DrugBank DB01060 (Amoxicillin); confirm via the DrugBank API and update drugbank_id in the evidence pack
[High] Capture MOA formally — populate original_moa field with the PBP-binding / cell wall synthesis inhibition mechanism after DrugBank linkage is confirmed
[High] Re-run TxGNN prediction pipeline — once DrugBank mapping is resolved, re-execute the KG and DL prediction steps to generate repurposing candidates
[Medium] Populate all licence fields — product name, dosage form, manufacturer, and approved indication text should be extracted from the NPRA record and stored for the next report version

⚠️ This report is for research reference only and does not constitute medical advice. All repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.